DongKook Pharmaceutical Co., Ltd. (086450.KQ)
KRW 16350.0
(-1.57%)
KRW 16350.0
(-1.57%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 66.87 Billion KRW | -7.45% |
| 2022 | 72.25 Billion KRW | 14.29% |
| 2021 | 63.21 Billion KRW | -23.47% |
| 2020 | 82.6 Billion KRW | 20.2% |
| 2019 | 68.71 Billion KRW | 24.68% |
| 2018 | 55.11 Billion KRW | 10.07% |
| 2017 | 50.07 Billion KRW | 6.7% |
| 2016 | 46.92 Billion KRW | 39.62% |
| 2015 | 33.6 Billion KRW | 26.57% |
| 2014 | 26.55 Billion KRW | 8.06% |
| 2013 | 24.57 Billion KRW | -9.18% |
| 2012 | 27.05 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 19.22 Billion KRW | -7.11% |
| 2024 Q1 | 20.69 Billion KRW | 1.12% |
| 2023 Q2 | 12.9 Billion KRW | -33.15% |
| 2023 FY | 66.87 Billion KRW | -7.45% |
| 2023 Q4 | 20.46 Billion KRW | 44.19% |
| 2023 Q3 | 14.19 Billion KRW | 9.94% |
| 2023 Q1 | 19.3 Billion KRW | 13.42% |
| 2022 Q4 | 17.02 Billion KRW | 43.54% |
| 2022 Q3 | 11.86 Billion KRW | -40.59% |
| 2022 Q2 | 19.96 Billion KRW | -14.72% |
| 2022 Q1 | 23.4 Billion KRW | 43.66% |
| 2022 FY | 72.25 Billion KRW | 14.29% |
| 2021 Q2 | 15.78 Billion KRW | -19.47% |
| 2021 Q1 | 19.6 Billion KRW | -0.24% |
| 2021 Q4 | 16.29 Billion KRW | 41.26% |
| 2021 Q3 | 11.53 Billion KRW | -26.95% |
| 2021 FY | 63.21 Billion KRW | -23.47% |
| 2020 Q2 | 18.29 Billion KRW | -5.63% |
| 2020 Q4 | 19.65 Billion KRW | -22.23% |
| 2020 FY | 82.6 Billion KRW | 20.2% |
| 2020 Q1 | 19.38 Billion KRW | -7.77% |
| 2020 Q3 | 25.27 Billion KRW | 38.15% |
| 2019 Q2 | 15.04 Billion KRW | 3.74% |
| 2019 FY | 68.71 Billion KRW | 24.68% |
| 2019 Q1 | 14.5 Billion KRW | 13.3% |
| 2019 Q4 | 21.01 Billion KRW | 15.84% |
| 2019 Q3 | 18.14 Billion KRW | 20.56% |
| 2018 Q2 | 13.41 Billion KRW | 5.36% |
| 2018 Q4 | 12.8 Billion KRW | -20.79% |
| 2018 Q3 | 16.16 Billion KRW | 20.51% |
| 2018 FY | 55.11 Billion KRW | 10.07% |
| 2018 Q1 | 12.73 Billion KRW | -18.77% |
| 2017 Q1 | 11.16 Billion KRW | -12.66% |
| 2017 Q4 | 15.67 Billion KRW | 26.08% |
| 2017 Q3 | 12.43 Billion KRW | 15.08% |
| 2017 Q2 | 10.8 Billion KRW | -3.21% |
| 2017 FY | 50.07 Billion KRW | 6.7% |
| 2016 FY | 46.92 Billion KRW | 39.62% |
| 2016 Q2 | 12.53 Billion KRW | 25.95% |
| 2016 Q1 | 9.95 Billion KRW | -10.46% |
| 2016 Q4 | 12.77 Billion KRW | 9.6% |
| 2016 Q3 | 11.66 Billion KRW | -6.97% |
| 2015 Q2 | 6.13 Billion KRW | 3.88% |
| 2015 Q1 | 5.9 Billion KRW | 1.65% |
| 2015 Q3 | 10.45 Billion KRW | 70.5% |
| 2015 Q4 | 11.11 Billion KRW | 6.28% |
| 2015 FY | 33.6 Billion KRW | 26.57% |
| 2014 Q3 | 7.71 Billion KRW | 22.13% |
| 2014 Q4 | 5.8 Billion KRW | -24.69% |
| 2014 FY | 26.55 Billion KRW | 8.06% |
| 2014 Q1 | 6.71 Billion KRW | 12.17% |
| 2014 Q2 | 6.31 Billion KRW | -6.0% |
| 2013 Q4 | 5.98 Billion KRW | -18.96% |
| 2013 FY | 24.57 Billion KRW | -9.18% |
| 2013 Q1 | 6.02 Billion KRW | -28.65% |
| 2013 Q2 | 5.16 Billion KRW | -14.29% |
| 2013 Q3 | 7.39 Billion KRW | 43.04% |
| 2012 FY | 27.05 Billion KRW | 0.0% |
| 2012 Q4 | 8.44 Billion KRW | -2.33% |
| 2012 Q3 | 8.65 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.54 Billion KRW | 442.2% |
| CMG Pharmaceutical Co., Ltd. | 5.72 Billion KRW | -1068.052% |
| Celltrion Pharm, Inc. | 36.07 Billion KRW | -85.395% |
| Huons Global Co., Ltd. | 122.92 Billion KRW | 45.598% |
| Enzychem Lifesciences Corporation | -14.35 Billion KRW | 565.817% |
| Humedix Co., Ltd. | 37.31 Billion KRW | -79.237% |
| Boditech Med Inc. | 33.44 Billion KRW | -99.962% |
| EuBiologics Co., Ltd. | 7.69 Billion KRW | -768.585% |
| FutureChem Co.,Ltd | -8.4 Billion KRW | 895.363% |
| Huons Co., Ltd. | 59.79 Billion KRW | -11.839% |
| BNC Korea Co., Ltd. | 10.81 Billion KRW | -518.128% |
| AptaBio Therapeutics Inc. | -16.37 Billion KRW | 508.423% |